CDC director to unvaccinated Americans: Keep your masks on

Biotechnology firm Novavax mentioned Friday that research in mice, baboons, and people counsel {that a} model of its coronavirus vaccine particularly developed to focus on the B.1.351 variant first recognized in South Africa can elicit “strong” immune responses.

That might point out it protects towards each the B.1.351 and the B.1.1.7 variant, first recognized within the United Kingdom, the corporate mentioned.

The research in contrast information on the B.1.351-directed vaccine with information on Novavax’s authentic coronavirus vaccine, the corporate famous, and the vaccines had been examined on their very own, together, and as primers or boosters. The findings revealed in a preprint paper on the medical server and the corporate mentioned the info have been submitted for peer overview.

“These data suggest that not only could one booster dose of this variant-directed vaccine potentially provide a robust, protective immune boost after vaccination against the original SARS-CoV-2 virus, but also the potential to provide broad protection against various virus strains if used as a primary vaccine regimen,” Dr. Gregory Glenn, president of analysis and improvement at Novavax, mentioned in an announcement.

“This broad immune coverage is vital to controlling the pandemic as variants of concern continue to emerge worldwide that could jeopardize the protection created through ongoing COVID-19 vaccination efforts,” Glenn mentioned.

In the rodent research, mice had been immunized with both the B.1.351 or authentic vaccine alone, together, or in a prime-boost sequence. Novavax introduced that whether or not immunized with any of these choices, mice had been protected when challenged with reside strains of the B.1.1.7 or B.1.351 variants. 

In the baboon research, the animals that had been immunized with the unique vaccine a 12 months earlier than had been boosted with one or two doses of the B.1.351 vaccine. Seven days after a primary increase, the baboons exhibited a robust immune response and the outcomes counsel one dose of the B.1.351 vaccine “may be sufficient” for enhancing after earlier immunizations with vaccines which might be based mostly on the unique virus pressure, the corporate mentioned.

In the human research, researchers analyzed serum samples collected from 30 folks collaborating in Phase 2 medical trials of Novavax’s authentic vaccine. The serum samples demonstrated neutralizing capability towards the B.1.1.7 variant, however there was a “modest reduction in neutralizing capacity” towards the B.1.351 pressure, the corporate famous, including that the discovering helps the event and manufacturing of a B.1.351 vaccine.


Leave a Reply

Your email address will not be published. Required fields are marked *